Free Research Reports on HCA, KWK, SCHW and THRX Issued by

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 19, 2013 at 8:17 PM

Free Research Reports on HCA, KWK, SCHW and THRX Issued by the Paragon Report

NEW YORK, NY--(Marketwired - Apr 16, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

HCA Holdings Inc. ( NYSE : HCA ) shares declined 4.18 percent on volume of 4.65 million shares traded Monday to close at $36.72 a share. The company announced that revenues for the first quarter of 2013 are expected to be approximately $8.440 billion compared to $8.405 billion in the first quarter of 2012.

Find out more about HCA Holdings including full access to the free equity report at: www.ParagonReport.com/HCA

Quicksilver Resources Inc. ( NYSE : KWK ) shares declined 10.36 percent on volume of 4.0 million shares traded Monday to close at $2.51 a share. Energy stocks fell sharply Monday as oil futures declined 3 percent to close at its lowest level of the year after China reported gross domestic product increase just 7.7 percent in the first quarter, down from growth of 7.9 percent in the previous quarter.

Find out more about Quicksilver Resources including full access to the free equity report at: www.ParagonReport.com/KWK

Charles Schwab Corp. ( NYSE : SCHW ) shares declined 3.82 percent on volume of over 10.5 million shares traded Monday to close at $16.62 a share. The company reported net income of $206 million for the first quarter of 2013, a decrease of 3 percent from the previous quarter, and an increase of 6 percent from the year ago quarter.

Find out more about Charles Schwab including full access to the free equity report at: www.ParagonReport.com/SCHW

Theravance Inc. ( NASDAQ : THRX ) shares surged 19.36 percent on volume of 4.74 million shares traded Monday to close at $28.36 a share. The FDA has released positive results from a review of Theravance's and partner GlaxoSmithKline's experimental inhaler drug, Breo Ellipta.

Find out more about Theravance including full access to the free equity report at: www.ParagonReport.com/THRX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information: Equity News Circuit Email Contact

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Top 5 Most Recently Viewed Articles

Investigation Launched for Block Investors This Spring

Investigation By Faruqi & Faruqi, LLP Faruqi & Faruqi, LLP, a prominent national securities litigation firm, is currently looking into issues concerning Block, Inc. (NASDAQ: SQ). The firm is focusing on claims related to alleged violations of federal securities laws that may have resulted in significant losses for investors. If you have experienced a loss of over $75,000...

Aviat Networks Faces Scrutiny After Annual Report Delay

Investor Concerns Escalate Amid Aviat Networks' Delay in Reporting Aviat Networks, Inc. (NASDAQ: AVNW) is facing a tough situation as its stock price suffered a notable decline, falling by $6.36, or around 26%, during intraday trading on a recent date. This drop followed the company's announcement that it would miss the deadline for filing its financial statements for the...

Tarsus Pharmaceuticals Prepares to Share Q2 2025 Results

Anticipating Tarsus Pharmaceuticals' Financial Report Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is gearing up to present its financial results for the second quarter of 2025 during a live webcast slated for Wednesday, August 6, 2025. This event will commence at 1:30 p.m. PT and 4:30 p.m. ET, providing a timely update on the company's performance and strategic...

Country Garden's Stock Recovers After Debt Restructuring Efforts

Country Garden’s Stock Trading Resumes with Momentum Recently, shares of Country Garden (HK: 2007), a prominent name in the Chinese property market, saw an impressive rise as trading resumed in Hong Kong after a lengthy suspension of nine months. This rebound came after the company's notable commitment to creating a debt-restructuring plan aimed at appealing to its...

Unlocking Long-Term Gains: Insights from Dollar Tree's Success

Dollar Tree's Remarkable Growth Over Two Decades Over the last 20 years, Dollar Tree (NASDAQ: DLTR) has become a major player in the retail market, demonstrating incredible resilience and expansion. If someone had put $1,000 into Dollar Tree stock two decades ago, that investment would have surged to more than $7,300 today. This change highlights the effectiveness of...